News Briefs

Ethiopia Ready to Start Nevirapine Trials for AIDS Treatment

November 20, 2002

This article is part of The Body PRO's archive. Because it contains information that may no longer be accurate, this article should only be considered a historical document.

Ethiopia's government is ready to begin testing nevirapine, used to prevent mother-to-child HIV transmission, the daily Addis Zemen reported. Health officials said initial trials of the drug would take place in five cities, including the capital Addis Ababa, following work to boost hospital capacity and ensure patient follow-up. Nevirapine could cut mother-to-child HIV transmission by 50 percent, according to HIV/AIDS experts at the Faculty of Medicine at the University of Addis Ababa. Between 6.4 percent and 7.3 percent of Ethiopia's adult population are estimated to be HIV-positive. Almost a million children in Ethiopia are AIDS orphans. Nevirapine is being provided free by a large pharmaceutical company, which the government daily did not name. The international drug company Boehringer-Ingelheim recently proposed to provide free nevirapine to developing countries.

Back to other CDC news for November 20, 2002

Previous Updates

Adapted from:
Agence France Presse

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.